Posted on

MSM, PrEP, and STIs: The Clinical Perspective

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Both the on-going syphilis and HIV epidemics are highly concentrated among men who have sex with men. While PrEP has been proven to reduce HIV transmission, it is not designed to prevent sexually transmitted infections like gonorrhea, syphilis, and chlamydia. What does the evidence say about reducing STI risk in MSM, and how can it be most effectively applied in practice? 

In this podcast, Dr. Matthew Spinelli — Assistant Professor in the Division of HIV, ID, and Global Medicine at the University of California, San Francisco and San Francisco General Hospital — takes us to the clinic to explain what providers can do to help their patients avoid acquiring and transmitting STIs. 

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

Increasing PrEP Uptake in PWID

Take our post-test to claim CME credits.

To read a companion newsletter click here.

People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of infection and improve their patients’ health? In this issue, Dr. Jessica Taylor from The Boston University School of Medicine and Boston Medical Center takes us into the clinic to explain how current evidence-based strategies can increase the uptake of HIV pre-exposure prophylaxis in this vulnerable population.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

“U=U” — Clinical Considerations

Volume 4, Issue 12

“U=U” — an Undetectable HIV viral load means Untransmittable HIV virus.  In her recent eHIV Newsletter Issue (Vol. 4; No. 11), Dr. Jill Blumenthal from the Division of Infectious Diseases and Global Public Health at the University of California San Diego analyzed the current evidence strongly supporting this concept.  In this Podcast, she discusses “U=U” from the clinical perspective, and models how it can help promote patient safety.

Take our post-test to claim CME credits.

To read a companion newsletter click here

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

In Clinical Practice: Overcoming Patient Barriers to PrEP

Volume 1, Issue 2

In this issue:

PrEP — pre-exposure prophylaxis to prevent HIV transmission — is safe, it’s effective, and it’s significantly underused in the U.S.  One key barrier to increased PrEP use is a lack of awareness and acceptance among the patient populations most at-risk for new HIV infection.

In this podcast, Dr. Douglas Krakower from Harvard Medical School takes us into the exam room to translate the new information in his Newsletter Issue into clinical practice.

Take our post-test to claim CME credits.

To read a companion newsletter click here

Podcast (eprimarycarereview): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

Emerging Promises and Challenges with the Use of Antiretroviral Therapy for Prevention of HIV Transmission

Volume 1, Issue 12.

Dr. Kenneth H. Mayer from Harvard discusses the important issues related to Pre-Exposure Prophylaxis (PrEP) in HIV-uninfected individuals at high-risk and reviews the results of several key studies that evaluated the use of PrEP.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS